Glueck C J
Ann Intern Med. 1982 Apr;96(4):475-82. doi: 10.7326/0003-4819-96-4-475.
Colestipol is a safe, effective, cholesterol-lowering, bile-acid sequestrant that lowers low-density-lipoprotein (LDL) and total plasma cholesterol levels without consistently affecting high-density-lipoprotein (HDL) cholesterol levels. Long-term colestipol therapy in conjunction with diet may reduce xanthoma size, arrest progression of coronary artery atherosclerosis, and may reduce mortality from coronary heart disease. Probucol, a bisphenol cholesterol-lowering drug, is an effective cholesterol-lowering agent that reduces levels of HDL cholesterol, HDL cholesterol, and apoprotein A-1, the major apolipoprotein of HDL. Because HDL cholesterol is independently and inversely associated with development of coronary heart disease, the ramifications of simultaneous lowering of LDL and HDL cholesterol levels by probucol treatment need further study. Long-term, placebo-controlled studies of repetitive coronary arteriography, coronary heart disease morbidity and mortality, or both are needed to ascertain the efficacy of long-term probucol use in relation to development of atherosclerosis.
考来烯胺是一种安全、有效的降胆固醇胆汁酸螯合剂，可降低低密度脂蛋白（LDL）和总血浆胆固醇水平，而对高密度脂蛋白（HDL）胆固醇水平无持续影响。考来烯胺长期治疗联合饮食可减小黄瘤大小，阻止冠状动脉粥样硬化进展，并可能降低冠心病死亡率。普罗布考是一种双酚类降胆固醇药物，是一种有效的降胆固醇药物，可降低HDL胆固醇、HDL胆固醇和载脂蛋白A-1（HDL的主要载脂蛋白）水平。由于HDL胆固醇与冠心病的发生独立且呈负相关，普罗布考治疗同时降低LDL和HDL胆固醇水平的影响需要进一步研究。需要进行长期、安慰剂对照的重复性冠状动脉造影、冠心病发病率和死亡率或两者的研究，以确定长期使用普罗布考对动脉粥样硬化发展的疗效。
